Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • EZ Cap™ Human PTEN mRNA (ψUTP): Cap1 mRNA for Enhanced PI...

    2025-10-25

    EZ Cap™ Human PTEN mRNA (ψUTP): Cap1 mRNA for Enhanced PI3K/Akt Pathway Inhibition

    Executive Summary: EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA encoding full-length human PTEN, stabilized by Cap1 and pseudouridine modifications for use in mammalian systems. This reagent enables efficient PI3K/Akt pathway inhibition by restoring PTEN function, critical for studies in cancer biology and drug resistance (Dong et al., 2022). Its Cap1 structure and ψUTP modifications suppress innate immune activation, enhance translation, and prolong mRNA stability in vitro and in vivo. The product is supplied at ~1 mg/mL, 1467 nucleotides in length, and is compatible with nanoparticle-mediated delivery. Strict handling protocols, including RNase-free conditions and storage at -40°C, are necessary to maintain RNA integrity (ApexBio R1026).

    Biological Rationale

    The PTEN gene encodes a lipid phosphatase essential for antagonizing PI3K activity and negatively regulating the Akt signaling pathway (Dong et al., 2022). Loss or inactivation of PTEN is commonly observed in multiple cancers and is associated with uncontrolled cellular proliferation, survival, and therapeutic resistance. Restoring PTEN expression, particularly via mRNA technologies, offers a direct mechanism to re-engage tumor suppressor pathways and inhibit oncogenic signaling [Related: Applied Strategies]. Unlike DNA or protein-based delivery, mRNA provides transient, non-integrating expression and can be rapidly tuned for experimental or therapeutic purposes.

    This article expands on the molecular mechanisms and translational potential of EZ Cap™ Human PTEN mRNA (ψUTP), clarifying its advantages over earlier pseudouridine-modified mRNA tools [See: Enhancing Functional mRNA].

    Mechanism of Action of EZ Cap™ Human PTEN mRNA (ψUTP)

    EZ Cap™ Human PTEN mRNA (ψUTP) introduces exogenous, capped, and polyadenylated PTEN mRNA into mammalian cells. The Cap1 structure—generated enzymatically using Vaccinia virus Capping Enzyme and 2'-O-Methyltransferase with GTP and SAM—optimizes recognition by the mammalian translation apparatus and reduces cytosolic pattern recognition receptor (PRR) activation (Dong et al., 2022). Pseudouridine triphosphate (ψUTP) substitutions further suppress innate immune sensors (e.g., TLR7, RIG-I, MDA5), enhance translation output, and increase mRNA half-life.

    Once delivered, the mRNA is translated in the cytoplasm to produce functional PTEN protein. PTEN acts on phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to reduce its levels, thereby suppressing PI3K/Akt signaling and downstream pro-proliferative and anti-apoptotic effects. This mechanism is central to reversing trastuzumab resistance in HER2+ breast cancer models, as persistent PI3K/Akt activation is a key driver of therapeutic failure (Dong et al., 2022). For more on how Cap1 and ψUTP enable immunoevasive delivery, see the update in [Next-Gen Immunoevasive mRNA].

    Evidence & Benchmarks

    • Systemic delivery of PTEN mRNA via nanoparticles in trastuzumab-resistant HER2+ breast cancer models restores PTEN expression and blocks PI3K/Akt signaling (Dong et al., 2022, DOI).
    • Pseudouridine-modified mRNA (ψUTP) demonstrates higher translation efficiency and reduced immunogenicity compared to unmodified mRNA in mammalian cells (Karikó et al., 2008, DOI).
    • Cap1-structured mRNA elicits less type I interferon response and is translated more robustly than Cap0 in human cell lines (Huang et al., 2020, DOI).
    • EZ Cap™ Human PTEN mRNA (ψUTP) is supplied at 1 mg/mL in 1 mM sodium citrate buffer, pH 6.4, with a poly(A) tail and length of 1467 nt, supporting reproducible transfection (ApexBio R1026, Product Page).
    • Strict handling—storage at -40°C or lower, use of RNase-free consumables—prevents degradation and preserves functionality (ApexBio R1026, Product Page).

    Applications, Limits & Misconceptions

    Primary Applications:

    • Functional studies of PTEN in cancer and cell signaling research.
    • Modeling and reversal of PI3K/Akt-driven drug resistance, especially in breast cancer systems.
    • Development and benchmarking of nanoparticle-mediated mRNA delivery platforms.
    • Exploration of innate immune modulation by mRNA modifications.

    This article updates recent findings on mRNA-based PI3K/Akt inhibition and clarifies translational use cases compared to [Transforming PI3K/Akt Pathway], especially regarding immunogenicity and delivery constraints.

    Common Pitfalls or Misconceptions

    • Direct addition of mRNA to serum-containing media leads to rapid degradation; always use a compatible transfection reagent.
    • Repeated freeze-thaw cycles degrade mRNA integrity; aliquot upon first thaw and avoid vortexing.
    • EZ Cap™ Human PTEN mRNA (ψUTP) does not integrate into the genome; effects are transient unless repeatedly dosed.
    • mRNA alone cannot overcome delivery barriers in vivo; nanoparticle or electroporation methods are required for systemic applications.
    • Cap1 and ψUTP modifications suppress but do not fully abrogate all innate immune responses, especially at very high doses.

    Workflow Integration & Parameters

    EZ Cap™ Human PTEN mRNA (ψUTP) is provided at approximately 1 mg/mL in 1 mM sodium citrate, pH 6.4. For optimal results, thaw on ice, aliquot to avoid multiple freeze-thaw cycles, and use exclusively with RNase-free reagents and consumables. The mRNA should be complexed with a transfection reagent (lipid-based or nanoparticle) for delivery into mammalian cells. Avoid direct addition to media containing serum without a carrier, as serum nucleases may rapidly degrade the mRNA.

    Store at -40°C or below. Do not vortex. Shipping is performed on dry ice to ensure stability. For in vivo studies, validated nanoparticle formulations are recommended to facilitate systemic delivery and tumor targeting, as demonstrated in mouse models of breast cancer resistance (Dong et al., 2022).

    For detailed practical strategies in advanced models, see [Unlocking Precision Oncology], which this article extends by providing up-to-date handling and benchmark protocols.

    Conclusion & Outlook

    EZ Cap™ Human PTEN mRNA (ψUTP) represents a next-generation tool for functional PTEN restoration and targeted inhibition of the PI3K/Akt pathway in cancer research. Its Cap1 and ψUTP modifications confer superior stability, translation, and immunoevasion compared to earlier mRNA formats. When integrated into nanoparticle delivery systems, the reagent enables robust reversal of drug resistance in preclinical models. Strict adherence to storage and handling protocols is necessary to maintain activity. Future studies will clarify its role in precision oncology and potential for therapeutic translation. Access the complete product dossier and protocol at EZ Cap™ Human PTEN mRNA (ψUTP) (R1026).